PCSK9 and COVID-19: Although not all studies support an association of PCSK9 expression and COVID-19 severity (Huang et al, 2021; Mester et al, 2023), the subcutaneous injection of evolocumab, a monoclonal inhibitory PCSK9 antibody, in patients with severe COVID-19 lowered the need for intubation and death.